Details for Patent: 8,524,746
✉ Email this page to a colleague
Which drugs does patent 8,524,746 protect, and when does it expire?
Patent 8,524,746 protects ONGENTYS and is included in one NDA.
This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: 8,524,746
| Title: | Dosage regimen for COMT inhibitors |
| Abstract: | The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. ##STR00001## |
| Inventor(s): | Learmonth; David Alexander (S. Mamede do Coronado, PT), Kiss; Laszlo Erno (S. Mamede do Coronado, PT), Palma; Pedro Nuno Leal (S. Mamede do Coronado, PT), Ferreira; Humberto dos Santos (S. Mamede do Coronado, PT), Silva; Patricio Manuel Vieira Araujo Soares da (S. Mamede do Coronado, PT) |
| Assignee: | Bial-Portela & Ca., S.A. (S. Mamede do Coronado, PT) |
| Application Number: | 12/524,848 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Recent additions to Drugs Protected by US Patent 8,524,746
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE | 212489 | Apr 24, 2020 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3869 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON’S DISEASE EXPERIENCING OFF EPISODES | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 8,524,746
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,524,746
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 07002091 | Jan 31, 2007 | |
| PCT Information | |||
| PCT Filed | October 10, 2007 | PCT Application Number: | PCT/PT2007/000043 |
| PCT Publication Date: | August 07, 2008 | PCT Publication Number: | WO2008/094053 |
International Family Members for US Patent 8,524,746
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 065098 | ⤷ Try a Trial | |||
| Argentina | 109590 | ⤷ Try a Trial | |||
| Australia | 2007346018 | ⤷ Try a Trial | |||
| Brazil | PI0721213 | ⤷ Try a Trial | |||
| Canada | 2678391 | ⤷ Try a Trial | |||
| China | 101631548 | ⤷ Try a Trial | |||
| Cyprus | 1118311 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
